| P50 | author | Paul Dyson | Q50080139 |
| | Gregory S Smith | Q56803397 |
| | Bruno Therrien | Q87642206 |
| P2093 | author name string | Catherine M Clavel | |
| | Preshendren Govender | |
| | Lara C Sudding | |
| P2860 | cites work | A short history of SHELX | Q25938995 |
| | Synthesis and cytotoxic activities of chloropyridylimineplatinum(II) and chloropyridyliminecopper(II) surface-functionalized poly(amidoamine) dendrimers | Q30921705 |
| | Development of organometallic ruthenium-arene anticancer drugs that resist hydrolysis | Q33260994 |
| | Luminescent dendritic cyclometalated iridium(III) polypyridine complexes: synthesis, emission behavior, and biological properties | Q33583909 |
| | Transferring the concept of multinuclearity to ruthenium complexes for improvement of anticancer activity | Q33640724 |
| | Unusual DNA binding modes for metal anticancer complexes | Q34071185 |
| | Organometallic ruthenium(II) diamine anticancer complexes: arene-nucleobase stacking and stereospecific hydrogen-bonding in guanine adducts | Q34119399 |
| | From bench to bedside--preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019 or FFC14A). | Q34511975 |
| | Dendrimers for pharmaceutical and biomedical applications | Q36367723 |
| | Metal-based antitumour drugs in the post genomic era. | Q36446191 |
| | Ruthenium complexes can target determinants of tumour malignancy | Q36764499 |
| | Cisplatin nephrotoxicity: mechanisms and renoprotective strategies | Q37084089 |
| | KP1019, a new redox-active anticancer agent--preclinical development and results of a clinical phase I study in tumor patients | Q37313183 |
| | Bioorganometallic chemistry--from teaching paradigms to medicinal applications | Q37377528 |
| | Current applications and future potential for bioinorganic chemistry in the development of anticancer drugs. | Q37603642 |
| | Targeted and multifunctional arene ruthenium chemotherapeutics | Q37920741 |
| | Polynuclear ruthenium, osmium and gold complexes. The quest for innovative anticancer chemotherapeutics | Q37951061 |
| | Maleimide-functionalised organoruthenium anticancer agents and their binding to thiol-containing biomolecules | Q39457114 |
| | Antiproliferative activity of chelating N,O- and N,N-ruthenium(II) arene functionalised poly(propyleneimine) dendrimer scaffolds | Q39619138 |
| | Ruthenium-porphyrin conjugates with cytotoxic and phototoxic antitumor activity | Q39701624 |
| | Maltol-derived ruthenium-cymene complexes with tumor inhibiting properties: the impact of ligand-metal bond stability on anticancer activity in vitro | Q39788647 |
| | Mono- and polynuclear [alkylamine]platinum(II) complexes of [1,2-bis(4-fluorophenyl)ethylenediamine]platinum(II): synthesis and investigations on cytotoxicity, cellular distribution, and DNA and protein binding | Q40322231 |
| | In vitro and in vivo evaluation of ruthenium(II)-arene PTA complexes | Q40412362 |
| | Inhibition of cancer cell growth by ruthenium(II) arene complexes | Q40774119 |
| | Controlling Platinum, Ruthenium and Osmium Reactivity for Anticancer Drug Design. | Q42576712 |
| | Control of tumour vascular permeability | Q45868243 |
| | The ruthenium(II)-arene compound RAPTA-C induces apoptosis in EAC cells through mitochondrial and p53-JNK pathways | Q46505331 |
| | Arene ruthenium(II) complexes formed by dehydrogenation of cyclohexadienes with ruthenium(III) trichloride | Q56528901 |
| | Systematic Design of a Targeted Organometallic Antitumour Drug in Pre-clinical Development | Q60212669 |
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1267-1277 | |
| P577 | publication date | 2013-01-01 | |
| P1433 | published in | Dalton Transactions | Q282900 |
| P1476 | title | The influence of RAPTA moieties on the antiproliferative activity of peripheral-functionalised poly(salicylaldiminato) metallodendrimers | |
| P478 | volume | 42 | |